Model for hepatitis C virus transmissions

  • Received: 01 October 2012 Accepted: 29 June 2018 Published: 01 June 2013
  • MSC : Primary: 34D20, 92D30; Secondary: 65L20, 93C15.

  • Hepatitis C virus (HCV) is a leading cause of chronic liver disease. Thispaper presents a deterministic model for HCV infection transmission and usesthe model to assess the potential impact of antiviral therapy. The model isbased on the susceptible-infective-removed-susceptible (SIRS) compartmentalstructure with chronic primary infection and possibility of reinfection.Important epidemiologic thresholds such as the basic and controlreproduction numbers and a measure of treatment impact are derived. We findthat if the control reproduction number is greater than unity, there is alocally unstable infection-free equilibrium and a unique, globallyasymptotically stable endemic equilibrium. If the control reproductionnumber is less than unity, the infection-free equilibrium is globallyasymptotically stable, and HCV will be eliminated. Numerical simulationssuggest that, besides the parameters that determine the basic reproductionnumber, reinfection plays an important role in HCV transmissions andmagnitude of the public health impact of antiviral therapy. Further,treatment regimens with better efficacy holds great promise for lowering thepublic health burden of HCV disease.

    Citation: Elamin H. Elbasha. Model for hepatitis C virus transmissions[J]. Mathematical Biosciences and Engineering, 2013, 10(4): 1045-1065. doi: 10.3934/mbe.2013.10.1045

    Related Papers:

  • Hepatitis C virus (HCV) is a leading cause of chronic liver disease. Thispaper presents a deterministic model for HCV infection transmission and usesthe model to assess the potential impact of antiviral therapy. The model isbased on the susceptible-infective-removed-susceptible (SIRS) compartmentalstructure with chronic primary infection and possibility of reinfection.Important epidemiologic thresholds such as the basic and controlreproduction numbers and a measure of treatment impact are derived. We findthat if the control reproduction number is greater than unity, there is alocally unstable infection-free equilibrium and a unique, globallyasymptotically stable endemic equilibrium. If the control reproductionnumber is less than unity, the infection-free equilibrium is globallyasymptotically stable, and HCV will be eliminated. Numerical simulationssuggest that, besides the parameters that determine the basic reproductionnumber, reinfection plays an important role in HCV transmissions andmagnitude of the public health impact of antiviral therapy. Further,treatment regimens with better efficacy holds great promise for lowering thepublic health burden of HCV disease.


    加载中
    [1] N. Engl. J. Med., 327 (1992), 1899-1905.
    [2] Clin. Infect. Dis., 46 (2008), 1852-1858.
    [3] J. Gastroenterol. Hepatol., 15 (2000), E105-E110.
    [4] Oxford University Press, Oxford, 1991.
    [5] Ann. Intern. Med., 144 (2006), 705-714.
    [6] Arch. Intern. Med., 167 (2007), 166-173.
    [7] J. Gastroenterol. Hepatol., 25 (2010), 1276-1280.
    [8] Ann. Intern. Med., 127 (1997), 55-65.
    [9] Int. Stat. Rev., 62 (1994), 229-243.
    [10] in "Quantitative Evaluation of HIV Prevention Programs" (Eds. Brookmeyer Kaplan ), (2002), 260-289. Yale University Press, New Haven.
    [11] Gut, 56 (2007), 385-389.
    [12] MMWR Recomm Rep., 47 (1998), 1-39.
    [13] 2010. (accessed October 5, 2012), http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm\#section1.
    [14] Recommendations and Reports, 61 (2012), 1-18.
    [15] Hepatology, 39 (2004), 74-80.
    [16] Hepatology, 31 (2000), 1014-1018.
    [17] J. Biol. Sys., 13 (2005), 331-339.
    [18] J. Math. Biol., 28 (1990), 365-382 .
    [19] J. R. Soc. Interface, 7 (2010), 873-885.
    [20] Nat. Biotechnology, 27 (2009), 305-306.
    [21] J. Infect. Dis., 198 (2008), 1651-1655.
    [22] Bull. Math. Biol., 70 (2008), 894-909.
    [23] Antivir Ther., 16 (2011), 1187-1201.
    [24] Hepatology, 49 (2009), 1335-1374.
    [25] Hepatology, 44 (2006), 1139-1145.
    [26] SIAM Rev., 42 (2000), 599-653.
    [27] Am. J. Gastroenterol, 103 (2008), 1283-1297.
    [28] 3rd edn. Prentice Hall, New York, 2002.
    [29] BMJ, 341 (2010), c3374.
    [30] Proc. Roy. Soc. Lond. A., 115 (1927), 700-721.
    [31] Transfusion, 49 (2009), 2454-2489.
    [32] in "Hepatitis C and Injecting Drug Use: Impact, Costs and Policy Options" (eds. J. C. Jager, W. Limburg, M. Kretzschmar, M. J. Postma and L. Wiessing), Lisbon: European Monitoring Centre For Drugs And Drug Addiction, (2004).
    [33] J. Virol., 76 (2002), 6586-6595.
    [34] J. Theor. Biol., 254 (2008), 178-196.
    [35] Math. Biosci., 182 (2003), 1-25.
    [36] J. Viral. Hepat., 15 (2008), 399-408.
    [37] J. Community Health, 33 (2008), 126-133.
    [38] Proc. Roy. Soc. Lond. B., 253 (1993), 9-13.
    [39] Lancet., 359 (2002), 1478-1483.
    [40] Science, 282 (1998), 103-107.
    [41] N. Engl. J. Med., 330 (1994), 744-750.
    [42] Gastroenterology, 138 (2010), 315-324.
    [43] Infec. Gene. Evol., 5 (2005), 131-139.
    [44] Crit. Rev. Immunol., 30 (2010), 131-148.
    [45] Math Biosci. Eng., 1 (2004), 81-93.
    [46] Nat. Med., 6 (2000), 578-582.
    [47] Math. Biosci., 180 (2002), 29-48.
    [48] Hepatology, 50 (2009), 1750-1755.
    [49] Transfusion, 42 (2002), 537-548.
    [50] http://www.who.int/mediacentre/factsheets/fs164/en/index.html (accessed October 29, 2012).
    [51] Drug Alcohol. Depend., 110 (2010), 228-233.
  • Reader Comments
  • © 2013 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(529) PDF downloads(695) Cited by(16)

Article outline

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog